Covington Firms Announce New Phase of Cancer-Fighting Drug's Study
Tue, 10/31/2017 - 19:59 RCN Newsdesk
There is another milestone to announce in the development of a cancer-fighting drug.
Covington-based Bexion Pharmaceuticals said Tuesday that it is starting Phase 1b of the study of BXQ-350. It's an open-label study in adult patients with advanced solid tumors.
In September, Bexion announced the successful completion of the first-in human Phase 1a trial, in which patients were enrolled at the University of Cincinnati, Ohio State University, the University of Kentucky, and the University of New Mexico.
In the Phase 1a trial, BXQ-350 was well tolerated at all five dose levels with no dose limiting toxicities observed and with no serious adverse events attributed to the therapy, the company reported. The highest dose is being utilized in the Phase 1b trial continuing at all four university sites.
BXQ-350 is based on technology developed by Dr. Xiaoyang Qi, then faculty member at Cincinnati Children’s Hospital Medical Center, which licensed the technology to
Bexion to continue development and ultimately commercialize the discovery.
Bexion is working with another Covington-based firm, CTI Clinical Trial and Consulting Services, on the project.
“It is very gratifying to witness Cincinnati Children’s cutting edge research progress into human clinical trials with the potential to improve patient care,” said Andrew Wooten, vice president of Cincinnati Children’s Center for Technology Commercialization. “Cincinnati Children’s has a rich history of research achievement and appreciates both Bexion’s and CTI Clinical Trial and Consulting Services’s commitment to bring this drug to patients.”
Bexion has partnered with CTI to advance BXQ-350 into human clinical trials. CTI is a global full-service contract research organization headquartered in greater Cincinnati/Northern Kentucky that has been a part of several dozen First-in- Human trials. The CTI team are experts in conducting and progressing clinical studies of life-changing therapies in critically ill cancer patients.
“CTI is delighted to partner with Bexion and Cincinnati Children’s to form a very strong regional cornerstone for drug development that will impact patients around the globe,” according to William Aronstein, PhD, MD, FACP, Vice President, Medical Affairs at CTI.
“We are honored to have licensed this technology from such a globally recognized research institution,” stated Dr. Ray Takigiku, Founder and CEO of Bexion. “Our goal was to develop an innovative drug from this technology to fight cancer. Together with CTI, Cincinnati Children’s, and our investigative sites, we are successfully moving forward in the development path towards that purpose.”
Photo: A lab at Bexion Pharmaceuticals (RCN file)